## LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-2 (Canceled).

- 3. (Currently Amended) A method for treating preparing a drug for the treatment of a neurodegenerative phase of multiple sclerosis in mammals, which method comprises administering to a mammal afflicted with the neurodegenerative phase of multiple sclerosis incorporating in said-drug a pharmaceutical formulation comprising a P2X7 purinergic receptor antagonist, wherein the antagonist is selected from the group consisting of Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP and HMA.
  - 4. (Previously Presented) The method of claim 3 wherein the antagonist is o-ATP.

Claims 5-9 (Canceled).